The SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) trial is a randomized trial supported by the National Institute of Health (NIH). More than 15 medical centers in the U.S., Canada and Europe are participating. The goal of the study is to determine if the Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure benefits patients with recurrent acute pancreatitis and pancreas divisum.
People who are 18 years old with no clear cause of pancreatitis are eligible. Participants must have had more than one attack of acute pancreatitis and may not have had a prior ERCP with minor papilla (incision) treatment or pancreas surgery.
The effects of ERCP on the risk of subsequent attacks of acute pancreatitis.
Participants will be randomized to either an endoscopic ultrasound (EUS) alone or EUS plus ERCP. During the follow-up period, we will study the occurrence of additional attacks of acute pancreatitis, pain, quality of life and progression to chronic pancreatitis. Participants will be compensated.
Up to four years.
Please visit the SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) trial website for more information.